| 排名 | 分析师 | 机构 | 行业 | 年度收益率 | 6个月收益率 | 3个月收益率 | 正收益比例 | 成分股数量 | 历史最大跌幅 | 更新日期 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 75.32% | 69.91% | 51.51% | 12.50% | 6 | -27.10% | 2025-06-04 |
| 2 | 唐寅灏 | 中信证券 | 医药生物 | 74.93% | 78.04% | 40.48% | 85.71% | 13 | -8.47% | 2025-08-07 |
| 3 | 阳景 | 浦银国际证券 | 医药生物 | 74.84% | 44.97% | 34.06% | 100.00% | 4 | 0.00% | 2025-09-26 |
| 4 | 唐寅灏 | 中信证券 | 医药生物 | 74.56% | 56.29% | 14.22% | 85.71% | 13 | -8.47% | 2025-09-09 |
| 5 | 刘浩 | 华创证券 | 医药生物 | 74.31% | 76.53% | 17.18% | 29.41% | 2 | -47.33% | 2025-07-15 |
| 6 | 刘浩 | 华创证券 | 医药生物 | 74.31% | 72.54% | 32.63% | 29.41% | 2 | -47.33% | 2025-07-25 |
| 7 | 唐寅灏 | 中信证券 | 医药生物 | 74.21% | 55.48% | 13.74% | 85.71% | 13 | -8.47% | 2025-09-15 |
| 8 | 唐寅灏 | 中信证券 | 医药生物 | 74.14% | 78.87% | 36.17% | 85.71% | 13 | -8.47% | 2025-08-11 |
| 9 | 唐寅灏 | 中信证券 | 医药生物 | 73.82% | 61.06% | 33.35% | 85.71% | 13 | -8.47% | 2025-08-28 |
| 10 | 唐寅灏 | 中信证券 | 医药生物 | 73.65% | 52.36% | 13.99% | 85.71% | 13 | -8.47% | 2025-09-11 |
| 11 | 阳景 | 浦银国际证券 | 医药生物 | 73.52% | 47.78% | 29.65% | 100.00% | 4 | 0.00% | 2025-09-10 |
| 12 | 刘浩 | 华创证券 | 医药生物 | 73.38% | 67.64% | 49.54% | 29.41% | 2 | -47.33% | 2025-06-13 |
| 13 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 73.28% | 73.28% | 22.66% | 12.50% | 7 | -27.10% | 2025-07-01 |
| 14 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 73.13% | 60.54% | 38.36% | 12.50% | 6 | -27.10% | 2025-06-06 |
| 15 | 唐寅灏 | 中信证券 | 医药生物 | 73.05% | 57.04% | 20.95% | 85.71% | 13 | -8.47% | 2025-09-25 |
| 16 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 72.98% | 81.77% | 32.08% | 12.50% | 7 | -27.10% | 2025-07-10 |
| 17 | 唐寅灏 | 中信证券 | 医药生物 | 72.94% | 52.48% | 12.18% | 85.71% | 13 | -8.47% | 2025-09-10 |
| 18 | 唐寅灏 | 中信证券 | 医药生物 | 72.94% | 52.10% | 21.01% | 85.71% | 13 | -8.47% | 2025-09-18 |
| 19 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 72.86% | 65.50% | 50.11% | 12.50% | 6 | -27.10% | 2025-06-03 |
| 20 | 唐寅灏 | 中信证券 | 医药生物 | 72.85% | 76.73% | 40.11% | 85.71% | 13 | -8.47% | 2025-07-25 |